Contents of this document
Earnings presentation materialsFY2027/3 Q25 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥52 million
Operating profit¥-685 million
Ordinary income¥-526 million
Net income¥-526 million
Selling, general and administrative expenses¥718 million
Results for the three months of the current quarter
Net Sales
¥52 million
DetailsSecond quarter: 1 ReHeart case
Full-year earnings forecast
Net Sales
¥540 million
Operating loss
¥-1,030 million
Ordinary loss
¥-580 million
Net loss attributable to owners of the parent
¥-570 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Full-year earnings forecast unchangedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Year-on-Year Decline in Revenue¥-140 million
- Decrease in cost of sales¥-58 million
- Decrease in gross profit¥-82 million
- Increase in selling, general and administrative expenses¥107 million
- Increase in R&D expenditure¥143 million
- Decline in funding received for joint research and development¥190 million
- Increase in non-operating income¥166 million
- Increase in non-operating expenses¥19 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- ReHeart transplant results in the second half3 Cumulative total of 3 cases by November
- Patients eligible for transplantation10 Example
New initiatives
- Study sessions and training seminars by regional block to expand ReHeart transplantation
- Joint research with Stanford University on second-generation iPS cardiomyocyte sheets
- Joint catheter research with Asahi Intecc
- Total funding of ¥4 billion through a third-party allotment capital increase and bond issuance
- Process development using a pilot-scale plant
Key KPIsA metric the company considers important as a management benchmark.
- ReHeart transplant results3 Example
- Patients eligible for transplantation10 Example
- Target for all-case post-marketing surveillance75 Example
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | FY2027/3 Q2 |
| Net Sales | ¥52 million |
| Operating profit | ¥-685 million |
| Ordinary income | ¥-526 million |
| Net income | ¥-526 million |
| Selling, general and administrative expenses | ¥718 million |
| Results for the three months of the current quarter | Net Sales ¥52 million / Details Second quarter: 1 ReHeart case |
| Full-year earnings forecast | Net Sales ¥540 million / Operating loss ¥-1,030 million / Ordinary loss ¥-580 million / Net loss attributable to owners of the parent ¥-570 million |
| Self-assessment against the plan | Full-year earnings forecast unchanged |
| Breakdown of Factors Affecting the Change | Factors Year-on-Year Decline in Revenue / Amount ¥-140 million, Factors Decrease in cost of sales / Amount ¥-58 million, Factors Decrease in gross profit / Amount ¥-82 million, Factors Increase in selling, general and administrative expenses / Amount ¥107 million, Factors Increase in R&D expenditure / Amount ¥143 million, Factors Decline in funding received for joint research and development / Amount ¥190 million, Factors Increase in non-operating income / Amount ¥166 million, Factors Increase in non-operating expenses / Amount ¥19 million |
| Key KPIs | Indicator name ReHeart transplant results / Value 3 Example / Year on year against the same period last year Not disclosed, Indicator name Patients eligible for transplantation / Value 10 Example / Year on year against the same period last year Not disclosed, Indicator name Target for all-case post-marketing surveillance / Value 75 Example / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | Item ReHeart transplant results in the second half / Value 3 Cumulative total of 3 cases by November, Item Patients eligible for transplantation / Value 10 Example |
| New initiatives | Study sessions and training seminars by regional block to expand ReHeart transplantation, Joint research with Stanford University on second-generation iPS cardiomyocyte sheets, Joint catheter research with Asahi Intecc, Total funding of ¥4 billion through a third-party allotment capital increase and bond issuance, Process development using a pilot-scale plant |
Items this document does not state (17)
Gross Profit MarginOperating profit marginProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.